6-K 1 v055902_6k.htm Unassociated Document
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
F O R M    6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of  October 2006

Prana Biotechnology Limited
(Name of Registrant)

Level 1, 100 Dorcas Street, South Melbourne, Victoria 3205 Australia
(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x         Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):_____ 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):_____

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o        No x

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-________
 

PRANA BIOTECHNOLOGY LIMITED

6-K Items

1.
Company highlights for the quarter ended 30 September 2006

Rule 4.7B
 
Appendix 4C - 1st Quarter

Quarterly report
for entities admitted
on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of Entity:
PRANA BIOTECHNOLOGY LIMITED


ABN:
  
Quarter Ended ('Current Quarter')
37 080 699 065
  
30th September 2006





Consolidated Statement of Cash Flows
     
 
Cash Flows Related to Operating Activities
Current Quarter
$A’000
Year to Date
(3 months)
$A’000
1.1
Receipts from customers
-
-
1.2
Payments for 
(a) staff costs
(b) advertising and marketing
(c) research and development
(d) leased assets
(e) other working capital
 
(488)
(6)
(1,785)
-
(552)
 
(488)
(6)
(1,785)
-
(552)
1.3
Dividends received
-
-
1.4
Interest and other items of a similar nature received
140
140
1.5
Interest and other costs of finance paid
-
-
1.6
Income taxes paid
-
-
1.7
Other (provide details if material)
-
-
 
Net Operating Cash Flows
(2,691)
(2,691)
 
+ See chapter 19 for defined terms.
30/9/2001
Appendix 4C

       
   
Current Quarter
$A’000
Year to Date
(3 months)
$A’000
1.8
Net Operating Cash Flows (carried forward)
(2,691)
(2,691)
 
 
Cash Flows Related to Investing Activities
-
-
1.9
Payment for acquisition of:
(a) businesses (item 5)
(b) equity investments
(c) intellectual property
(d) physical non-current assets
(e) other non-current assets
 
-
-
-
-
-
 
-
-
-
-
-
1.10
Proceeds from disposal of: 
(a) businesses (item 5)
(b) equity investments
(c) intellectual property
(d) physical non-current assets
(e) other non-current assets
 
-
-
-
-
-
 
-
-
-
-
-
1.11
Loans to other entities
-
-
1.12
Loans repaid by other entities
-
-
1.13
Other (provide details if material)
-
-
 
 
Net Investing Cash Flows
-
-
1.14
Total Operating and Investing Cash Flows
(2,691)
(2,691)
 
 
Cash Flows Related to Financing Activities
    
1.15
Proceeds from issues of shares, options, etc.
43
43
1.16
Proceeds from sale of forfeited shares
-
-
1.17
Proceeds from borrowings
-
-
1.18
Repayment of borrowings
-
-
1.19
Dividends paid
-
-
1.20
Other (provide details if material)
-
-
 
Net Financing Cash Flows
-
-
 
 
Net Increase / (Decrease) in Cash Held
 
(2,648)
 
(2,648)
1.21
Cash at beginning of quarter/year to date
10,014
10,014
1.22
Exchange rate adjustments to item 1.20
(148)
(148)
1.23
Cash at End of Quarter
7,218
7,218
 
+ See chapter 19 for defined terms.

30/9/2001
Appendix 4C

Payments to Directors of the Entity and Associates of the Directors
 
Payments to Related Entities of the Entity and Associates of the Related Entities
   
 
Current Quarter
$A'000
 
1.24
 
Aggregate amount of payments to the parties included in item 1.2
 
170
 
1.25
 
Aggregate amount of loans to the parties included in item 1.11
 
-
 
1.26
 
Explanation necessary for an understanding of the transactions
 
 
 
Salaries, directors’ fees and consulting fees at normal commercial rates
 

Non-Cash Financing and Investing Activities
 
2.1
Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows
 
 
-

2.2
Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest
 
 
-

Financing Facilities Available
Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).
       
   
Amount Available
$A’000
Amount Used
$A’000
3.1
Loan facilities
 
-
-
3.2
Credit standby arrangements
 
-
-
 
+ See chapter 19 for defined terms.
30/9/2001
Appendix 4C
 
Reconciliation of Cash
     
Reconciliation of cash at the end of the quarter
(as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.
Current Quarter
$A’000
Previous Quarter
$A’000
4.1
Cash on hand and at bank
757
684
4.2
Deposits at call
6,461
9,330
4.3
Bank overdraft
-
-
4.4
Other (provide details)
-
-
 
Total: Cash at End of Quarter (item 1.22)
7,218
10,014


Acquisitions and Disposals of Business Entities
     
 
Acquisitions
(Item 1.9(a))
Disposals
(Item 1.10(a))
5.1
Name of entity
-
-
5.2
Place of incorporation or registration
-
-
5.3
Consideration for
acquisition or disposal
-
-
5.4
Total net assets
-
-
5.5
Nature of business
-
-

Compliance Statement

1
This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.

2
This statement does give a true and fair view of the matters disclosed.
 
 
 
Sign Here: Date: 30 October 2006
       
  Company Secretary    
       
Print Name: Richard Revelins    
 
The CFO Solution
www.thecfo.com.au 
 
+ See chapter 19 for defined terms.

30/9/2001
Appendix 4C

Notes

1.
The quarterly report provides a basis for informing the market how the entity’s activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.

2.
The definitions in, and provisions of, AASB 1026: Statement of Cash Flows apply to this report except for the paragraphs of the Standard set out below.

· 6.2
- reconciliation of cash flows arising from operating activities to operating profit or loss
  · 9.2 - itemised disclosure relating to acquisitions
  · 9.4 - itemised disclosure relating to disposals
  · 12.1(a) - policy for classification of cash items
  · 12.3 - disclosure of restrictions on use of cash
  · 13.1 - comparative information

3.
Accounting Standards. ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.

30/9/2001
Appendix 4C

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
     
 
PRANA BIOTECHNOLOGY LIMITED
(Registrant)
 
 		  
 		  
 
  By:   /s/ Geoffrey Kempler
 
Geoffrey Kempler,
  Executive Chairman

Date:  October 30, 2006